Renaissance Technologies’s Enveric Biosciences ENVB Stock Holding History

Renaissance Technologies’s Portfolio ENVB Stock Details ENVB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-3,084	Closed	-$44.8K	–	3601
2025 Q2	$44.8K	Buy	+3,084	New	+$46.7K	﹤0.01%	3409
2023 Q3	–	Sell	-95	Closed	-$58K	–	3769
2023 Q2	$58K	Buy	+95	New	+$46.2K	﹤0.01%	3586
2022 Q3	–	Sell	-121	Closed	-$234K	–	4102
2022 Q2	$234K	Sell	121 -100	-45%	-$213K	﹤0.01%	3578
2022 Q1	$657K	Buy	221 +159	+256%	+$702K	﹤0.01%	3008
2021 Q4	$515K	Buy	62 +7	+13%	+$98.4K	﹤0.01%	3060
2021 Q3	$1.02M	Buy	+55	New	+$1.07M	﹤0.01%	2534
2019 Q3	–	Hold	0	–	-$56K	–	3487
2019 Q2	–	Hold	0	–	–	–	3444
2019 Q1	–	Hold	0	–	-$12K	–	3502
2018 Q4	–	Hold	0	–	–	–	3332

Other funds holding ENVB

AdvisorShares Investments Bethesda, Maryland $549M AUM 32.58% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SBI Securities Tokyo, Japan $3.65B AUM 41.88% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

National Bank of Canada Montreal, Quebec, Canada $112B AUM 31.26% 1-Year Est. Return

Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

Renaissance Technologies's ENVB Position: Q3 2025 in Review

Renaissance Technologies sold out of Enveric Biosciences (ENVB) in Q3 2025, closing a stake of 3,084 shares — an estimated $44.8K sold.

Renaissance Technologies first reported a position in ENVB in Q3 2021 and held it in 6 quarters. The position peaked at $1.02M in Q3 2021. 8 funds tracked by Wall St. Rank hold ENVB as of Q3 2025.

Renaissance Technologies reported no remaining Enveric Biosciences position as of Q3 2025 after selling out during the quarter.
Renaissance Technologies sold 3,084 Enveric Biosciences shares in Q3 2025, an estimated $44.8K.
Renaissance Technologies first reported a position in Enveric Biosciences in Q3 2021 and held it in 6 quarters.
Renaissance Technologies's Enveric Biosciences position peaked at $1.02M in Q3 2021.
8 funds tracked by Wall St. Rank held Enveric Biosciences as of Q3 2025.

Based on Renaissance Technologies's 13F filing for Q3 2025, filed 13 Nov 2025.